Metronidazole 500mg/100 ml Injectable Vial
Antibiotic of the family of nitro-5 Imidazol (J: Anti-infectious)
Intravenous injection of 500 mg of metronidazole produces after a single infusion an average peak of 18 mg/l at the end of a 20-minutes infusion.
Repeat infusion :
- every 8 hours produces the same average peak,
- every 12 hours an average peak of 13 mg/l.
Plasma half-life is from 8 to 10 hours. Serum proteins binding of metronidazole is low (<10 %). Distribution is fast and large in the lungs, kidneys, liver, skin, bile, CSF, saliva, seminal liquid, vaginal secretions. It crosses the placental barrier and passes into the breast milk.
Metronidazole produces primarily two metabolites with no conjugation and endowed with
antibacterial activity (10 to 30%).
Metronidazole concentrates primarly on liver and bile, its colic concentration is low. Major path of excretion is in urine (40 to 70 %, with about 20 % unchanged ), inducing a brownreddish coloration of urine. In patients with renal insufficiency, elimination half-life is unchanged and no dose adjustment is required. In hemodialysis, metronidazole is rapidly eliminated and half-life reduced to 2 hours 30.
Therapeutic Indications of metronidazole
They derive from metronidazole antibacterial and antiparasitic activity and its pharmacokinetic properties. They are restricted to infections caused by germs known as sensitive :
- Curative treatment of medico-surgical infections with sensitive anaerobic germs;
- Prophylaxis of post-operative infections to sensitive anaerobic germs in digestive or proctologic surgical operations, associated with an active antibiotic on aerobic germs;
- Severe amoebiasis occurring in intestinal or hepatic sites
Injectable metronidazole must be used for patients in whom oral use is not indicated.
The official recommendations on appropriate use of antibacterials should be taken into consideration.
Contacts to get additional informations on the product